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In This IssueImage source: The website of the National Cancer
Institute (http://www.cancer.gov)Metabolite Proﬁles of the Serum of Patients with Non–Small
Cell Carcinoma
The study proﬁled serum metabolites from patients with un-
treated stage I–III non–small cell lung cancer (NSCLC) and
controls who were at risk to develop models that could
differentiate lung cancer patients from control subjects.
Metabolite concentrations and ratios of metabolite concentra-
tions in cancer patients were compared with those of controls,
matched for demographic and comorbidity characteristics. Of
the 284 subjects analyzed (aged an average of 67 years, 48%
female), there were 94 lung cancer patients of which 50 had
adenocarcinoma, 44 had squamous cell lung cancer, 44% were
stage I, 17% stage II, and 39% stage III. Of the 534 metabolites
identiﬁed in multiple metabolite super-pathways and sub-
pathways, 149 metabolites were found with signiﬁcantly
different concentrations between the cancer (70 lower, 79
higher) and control groups (q values < 0.05). Signiﬁcant dif-
ference in 9723 metabolite ratios was also observed between
the cancer and control groups (q values < 0.001). C-statistics,
indicating model accuracies, for models trained on 70% of the subjects and tested on 30% ranged from 0.748 to
0.858. In summary, the ﬁndings demonstrated differences in serum metabolite proﬁle between patients with stage
I–III NSCLC and matched controls. Further studies on these differences could lead to development of novel bio-
markers and targeted therapy. (p. 72)Three-Year Follow-Up of a
Randomized Phase II Trial
on Reﬁnement of Early-
Stage NSCLC Adjuvant
Chemotherapy with Cisplatin
and Pemetrexed versus
Cisplatin and Vinorelbine
(the TREAT Study)
The TREAT study was aimed
to compare the feasibility of
two adjuvant regimens
(cisplatin and vinorelbine
[CVb] and cisplatin and
pemetrexed [CPx]) in 132
early-stage NSCLC patients.
The primary end point anal-
ysis has demonstrated supe-
riority of CPx over CVb on
safety, feasibility, and dose
delivery. This report of a 3-
year follow-up provides data on the secondary end points: overall survival (OS), relapse-free, distant metastases-free,
and local relapse-free survivals. No signiﬁcant differences between CVb and CPx were observed in any outcomeJournal of Thoracic Oncology Vol. 11 No. 1: 1-7
2 Journal of Thoracic Oncology Vol. 11 No. 1parameters after a median of 39 months. Despite signiﬁcant association of OS at 3 years with feasibility and dose
limiting toxicity (DLT), histology and tumor size of stage IB were not correlated with survival in the CPx arm. In
summary, the study demonstrated adjuvant chemotherapy with CPx is safe with reduced toxicity and better dose
delivery versus CVb, and OS is affected by feasibility and DLT but not treatment arm in this phase II trial. The
authors suggested use of longer follow-up times or surrogate survival end points in future studies of the effect of
this regimen on survival of early stage NSCLC. (p. 85)Lymph Node Dissection in Thymic Malignancies: Implica-
tion of the ITMIG Lymph Node Map, TNM Stage Classiﬁca-
tion, and Recommendations
The retrospective study analyzed 131 thymic malignancy
patients undergone lymph node dissection (LND) based on
the recently introduced ITMIG/IASLC nodal map and TNM
stage classiﬁcation to evaluate the lymphatic metastasis
pattern and factors of lymphatic metastasis. Thirteen pa-
tients had node metastasis (6 N1, 7 N2), of which 86% of
N2 patients had right paratracheal node (RPN) metastases.
The node metastasis rates were 1% at T1 and 37.5% at
T2/3 (p < 0.001), 8% in the M0 and 43% in the M1 (p ¼
0.03); higher rate was observed in thymic carcinoma
versus thymoma (25% versus 5.1%; p ¼ 0.01), and vari-
able rates were also found between thymoma subtypes. No
node metastasis was found in A, AB, and B1 subtypes.
Preoperative histologic diagnosis was given to 16% of the
patients. Signiﬁcant associations were observed between node metastasis and tumor size, with a 6 cm optimal cutoff
value and a speciﬁcity of 62%, and TNM stage greater than or equal to II thymic malignancy. Signiﬁcantly worse
5-year recurrence-free rate was found in patients with pN1/2 versus those with pN0 (38.5% versus 87.9%; p <
0.001). Taken together, the ﬁndings demonstrated that the RPN was important for lymphatic metastasis and a TNM
stage greater than or equal to II in thymic malignancies. The authors suggested modiﬁcation of the ITMIG recom-
mendation for LND to include RPN in stage II or above thymic malignancies. (p. 108)55 Trials
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[391 Consents]Patients with Advanced Non–Small Cell Lung Cancer: Are
Research Biopsies a Barrier to Participation in Clinical
Trials?
The authors aimed to investigate the effect of performing
research biopsies on clinical trial enrollment for patients
with advanced NSCLC at the Princess Margaret Cancer
Centre (2007–2015). The review of 55 clinical trials
identiﬁed 38 that required tumor samples for enrollment,
6 that mandated repeat biopsies while 32 accepted
archival samples. Therapeutic trial participation was
offered in 549 study encounters, with a 60% participation
rate. Study treatment participation was higher and treat-
ment started earlier in trials without versus with mandated biopsy requirement (83% versus 55%; p < 0.0001 and
9 versus 16 days; p ¼ 0.002, respectively). Comparison of trials allowing archival tissue to those mandating repeat
biopsies showed similar result. Absence of a required biomarker (34%), consent withdrawal (20%), deterioration/
death (17%), other exclusion criteria (15%), and insufﬁcient biopsy tissue (10%) were the most common barriers to
trial participation. In summary, this study indicates that requirement of tumor biopsies for NSCLC trial enrollment and
treatment eligibility signiﬁcantly hinders trial enrollment. Therefore, the role of research biopsies in clinical trials
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biomarkers, should be implemented. (p. 79)
Research Watch
Extended Survival and Prognostic Factors for Patients with ALK-Rearranged Non–Small Cell Lung Cancer
and Brain Metastasis
The study evaluated prognostic factors and outcomes in 90 patients with ALK-rearranged non–small cell lung cancer
(NSCLC) and brain metastasis, who received stereotactic radiosurgery (SRS) or whole-brain radiotherapy (WBRT)
(n ¼ 84), and/or tyrosine kinase inhibitor (TKI) therapy (n ¼ 86). This cohort achieved a median overall survival
(OS) of 49.5 months, and median intracranial progression-free survival of 11.9 months. Progressive brain metastases
at death were found in 45% of patients, with repeated interventions for brain metastases being common. Prolonged
survival was associated with absence of extracranial metastases (ECM), Karnofsky performance score (KPS) greater
than or equal to 90, and no TKI therapy prior to developing brain metastases (p ¼ 0.003, < 0.001, and < 0.001,
respectively). No survival difference were observed in those with single brain metastasis versus greater than 1
metastasis (p ¼ 0.633), and in those receiving initial treatment with SRS versus WBRT (p ¼ 0.666). Multivariable
analysis demonstrated that absence of ECM, no prior treatment with ALK-targeted TKIs, and KPS greater than or
equal to 90 were independent predictors of OS, which were used to describe four patient groups with 2-year OS
estimates of 33%, 59%, 76%, and 100%, respectively (p < 0.001). To conclude, the survival beneﬁts achieved by
patients with brain metastasis from ALK-rearranged NSCLC treated with SRS and/or WBRT and TKIs indicate the
signiﬁcance of interventions to control intracranial disease. The prognostic factors identiﬁed in this study could help
stratify patients likely to beneﬁt from ﬁrst-line SRS, close CNS observation, and treatment of emergent CNS disease.
Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non–
small-cell lung cancer and brain metastasis [e-pub ahead of print]. J Clin Oncol. http://dx.doi.org/10.1200/jco.2015.
62.0138, accessed November 10, 2015.
Role of Chemoradiotherapy in Elderly Patients with Limited-Stage Small-Cell Lung Cancer
The authors assessed the survival beneﬁts of chemotherapy (CT) alone compared with chemoradiotherapy (CRT) in
elderly patients aged greater than or equal to 70 years with limited-stage small-cell lung cancer (SCLC) in a large
National Cancer Data Base (2003–2011). Of the 8637 patients identiﬁed, CT was given to 43.7% and CRT to 56.3%.
Univariate and multivariate analysis showed increased median overall survival (OS) with CRT versus CT (15.6 versus
9.3 months; hazard ratio, 0.52; p < 0.001). Subset analysis of CRT treatment sequence demonstrated median OS of
17.0 months in patients alive 4 months after diagnosis from concurrent CRT versus 15.4 months from sequential CRT
(p ¼ 0.01). Increasing age, clinical stage III disease, female sex, and presence of comorbidities were associated with
decrease likelihood of receiving CRT. The ﬁndings suggest additional survival advantage for elderly patients with
limited-stage SCLC receiving CRT versus CT alone, supporting the potential of CRT as the preferred approach in this
patient population.
CorsoCD,RutterCE, ParkHS, et al. Role of chemoradiotherapy inelderlypatientswith limited-stage small-cell lung cancer
[e-pub ahead of print]. J Clin Oncol. http://dx.doi.org/10.1200/jco.2015.62.4270, accessed November 10, 2015.
Comparative Study of the PD-L1 Status between Surgically Resected Specimens and Matched Biopsies of
NSCLC Patients Reveal Major Discordances: A Potential Issue for Anti-PD-L1 Therapeutic Strategies
The study compared the expression of programmed death ligand-1 (PD-L1) on tumor cells (TC) and tumor-
inﬁltrating immune cells (IC) in whole surgical tissue sections with that in matched lung biopsies of 160 patients
with operable NSCLC. The overall discordance rate of 48% and poor agreement (k-value ¼ 0.218) were observed
between PD-L1 expression in resected specimens and that in matched biopsies. All cases revealed lower PD-L1
expression in the biopsy specimens compared with the whole tissue specimen. The major discrepancies between
resected specimens and matched biopsies were the lack of a PD-L1-positive IC component in the former while the
4 Journal of Thoracic Oncology Vol. 11 No. 1latter had more common PD-L1-positive IC than PD-L1-positive TC. Taken together, the ﬁndings suggest poor as-
sociation of PD-L1 expression in TC and IC between resected tumors and matched biopsies in the NSCLC population
studied. If conﬁrmed in further studies with larger cohorts, the discordance of PD-L1 observed could impact the
routine diagnostic assessment of PD-L1 expression in biopsies, stratifying patients for PD-L1 targeted therapies.
Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and
matched biopsies of NSCLC patients reveal major discordances. A potential issue for anti-PD-L1 therapeutic stra-
tegies [e-pub ahead of print]. Ann Oncol. http://dx.doi.org/10.1093/annonc/mdv489, accessed November 10, 2015.
Clinical Application of Amplicon-Based Next-Generation Sequencing to Therapeutic Decision Making in Lung
Cancer
This prospective study analyzed tumor specimens from 110 lung cancer patients using amplicon sequencing panel
(mutational hotspots in 22 genes related to lung and colon tumorigenesis, and 72 major variants of ALK, RET, ROS1,
and NTRK1 fusion transcripts), and correlated patients given genotype-directed therapy with their overall survival
(OS). TP53mutations were most commonly found (n¼ 42), followed by EGFRmutations (n¼ 25), STK11mutations (n
¼ 12), and KRAS mutations (n ¼ 10). Potentially actionable mutations were found in 44 patients, of which 50% had
adenocarcinoma and 14% had squamous cell carcinoma. Signiﬁcantly prolonged OS was observed in patients with an
actionable mutation and treated with targeted therapy (median not reached) versus those without mutation (18.1
months, p¼ 0.041) or those with a mutation but no treatment (6.1 months, p¼ 0.0027). Multiplex genomic testing on
formalin-ﬁxed, parafﬁn-embedded tumor specimens demonstrated greater than or equal to 95% success rate. These
ﬁndings support multiplex genomic testing in guiding clinical decisions on approved or experimental treatments.
Takeda M, Sakai K, Terashima M, et al. Clinical application of amplicon-based next-generation sequencing to ther-
apeutic decision making in lung cancer [e-pub ahead of print]. Ann Oncol. http://dx.doi.org/10.1093/annonc/
mdv475, accessed November 10, 2015.
The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial
The study evaluated the impacts of smoking history and abstinence on mortality in high-risk individuals who took
part in the National Lung Screening Trial (NLST). The analysis included self-reported demographics, medical and
smoking history, lung cancer-speciﬁc and all-cause mortality. Regardless of screening arm, higher lung cancer-
speciﬁc and all-cause mortality were observed in current smokers versus former smokers (hazard ratio, HR range
2.14–2.29 and 1.79–1.85, respectively). Comparable to reported outcome of LDCT screening in the NLST, a 20%
reduction in mortality was observed in former smokers in the control arm with 7-year abstinence. The maximum
beneﬁt, with a 38% reduction of lung cancer-speciﬁc mortality, was observed in the group with LDCT screening
combined with smoking abstinence at 15 years (HR 0.62). To conclude, the ﬁndings underscore the impacts of
smoking cessation in lung cancer screening: lung cancer-speciﬁc mortality reduction is comparable between in-
dividuals with 7-year smoking abstinence and those received LCDT screening, and it is improved when abstinence is
combined with screening.
Tanner NT, Kanodra NM, Gebregziabher M, et al. The association between smoking abstinence and mortality in the
National Lung Screening Trial [e-pub ahead of print]. Am J Respir Crit Care Med. http://dx.doi.org/10.1164/rccm.
201507-1420OC, accessed November 10, 2015.
First Tobacco Product Tried: Associations with Smoking Status and Demographics Among College Students
The study was a cross-sectional web survey investigating product choice for initial tobacco trial, correlates asso-
ciated with it, and the associations between ﬁrst product and current cigarette smoking among 3146 ﬁrst-year
students across 11 universities in North Carolina and Virginia. The analysis demonstrated a 48.6% weighted
prevalence of ever use of tobacco. The most common ﬁrst product was cigarette (37.9%), followed by cigars (29.3%),
hookahs (24.6%), smokeless tobacco (6.1%), and bidis/kreteks (2.2%). Among current smokers, 65% started with
cigarettes, 16.4% with cigars, 11.1% with hookahs, 5.7% with smokeless tobacco, and 1.7% with bidis/kreteks. The
ﬁrst products for females were more likely cigarettes and hookahs, and for males were cigars and smokeless tobacco.
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while hookahs and cigars were associated with age greater than or equal to 18 years. Starting with hookahs and
smokeless tobacco were associated with dual or poly tobacco use. In summary, the data showed that two thirds of
students started with non-cigarette products and about a third of current cigarette smokers started with a non-
cigarette product, supporting the possibility of non-cigarette products leading to cigarette smoking.
Sutﬁn EL, Sparks A, Pockey JR, et al. First tobacco product tried: associations with smoking status and demographics
among college students. Addict Behav. 2015;51:152–157, http://dx.doi.org/10.1016/j.addbeh.2015.07.022.
News-in-BriefImage source: The website of the National Cancer
Institute (http://www.cancer.gov)FDA Approves Use of Nivolumab in Advanced Nonsquamous
Lung Cancer
The FDA has expanded the indication of nivolumab to treating
patients with advanced nonsquamous non–small cell lung
cancer (NSCLC) whose disease progressed on or after
platinum-based chemotherapy. Nivolumab was approved
earlier this year by the agency for the treatment of patients
with advanced squamous NSCLC following chemotherapy. The
approval was based on the ﬁndings of the trial comparing ef-
ﬁcacy and safety of nivolumab with docetaxel. Nivolumab
demonstrated superior activity versus docetaxel: overall sur-
vival of 12.2 months versus 9.4 months, and complete or
partial response of 19% (lasted average 17 months) versus
12% (lasted average 6 months). Its efﬁcacy was also associated
with PD-L1 expression in NSCLC tumors.ASTRO 2015: IMRT Associated with Less Toxicity and
Better Tolerance to Chemotherapy than 3-D CRT in
Lung Cancer
A secondary analysis of data from the large phase III
randomized trial (NRG/RTOG 0617) of patients with
locally advanced NSCLC compared 3-dimensional conformal radiation therapy (3-D CRT) and intensity modulated
radiation therapy (IMRT), in addition to concurrent chemotherapy. Of the 482 patients treated with radiation, 53%
received IMRT and 47% received 3-D CRT. Severe pneumonitis cases were reduced by 44% in the IMRT arm versus
the 3-D CRT arm (3.5% versus 7.9%), across tumor size, with more pronounced effect in larger tumors. The IMRT
arm was also more likely to complete consolidative chemotherapy (37% versus 29%). In summary, patients with
locally advanced NSCLC had less severe lung toxicity and improved tolerance of chemotherapy, when given IMRT
compared to 3-D CRT. Despite being more time-sensitive and costly, the ﬁndings indicate that IMRT could reduce
number of hospital admissions and improve quality of life for this patient population.
News from the IASLC Tobacco Control Committee
Another TPPA Update
It takes a while to ﬁnd it through the maze of the Internet and Wikipedia and the like, but you can download the
entire (vast) text of the TPPA through this link: http://dfat.gov.au/trade/agreements/tpp/ofﬁcial-documents/Pages/
ofﬁcial-documents.aspx. Last month’s column was very pleased to note the provision for tobacco control within the
TPPA, reported on before the text was released. Well, maybe the news is not so good. Bilaterals.org (an international,
collaborative watchdog website for the trade and investment world) has expressed grave concern about the actual
6 Journal of Thoracic Oncology Vol. 11 No. 1text of the TPPA with regard to tobacco control.1 It is complex reading for non-industrial relations and trade bofﬁns,
but in the article the writers make the following points:
 Chapter 29 of the TPP states that “any TPP nation has the right to ‘elect to deny’ access to a trade dispute by
corporations for “claims challenging a tobacco control measure.” That sounds good (Ed.).
 However, in a footnote the text gives to government “the right to challenge each other’s tobacco control measures.”
Remember that quite a lot of Big Tobacco is state-owned around the world.
 In another footnote, the text tells us that while a “tobacco control measure” can apply to “manufactured tobacco
products . their distribution, labeling,” etc., this does not apply to “tobacco leaf that is not in the possession of
manufacturer” or “that is not part of a manufactured tobacco product.”
Sigh ..
E-Cigarette Data from the United States
The CDC and National Centre for Health Statistics released the ﬁrst set of data on e-cigarette use amongst US adults
this October.2 The data come from a 2014 survey of just under 37,000 adults and made the following key ﬁndings:
In 2014, 12.6% of adults had ever tried an e-cigarette even one time, with use differing by sex, age, and race, and
Hispanic or Latino origin.
About 3.7% of adults currently used e-cigarettes, with use differing by age, and race, and Hispanic or Latino origin.
Current cigarette smokers and former smokers who quit smoking within the past year were more likely to use
e-cigarettes than former smokers who quit smoking more than 1 year ago and those who had never smoked.
Among current cigarette smokers who had tried to quit smoking in the past year, more than one-half had ever tried an
e-cigarette and 20.3% were current e-cigarette users.
Among adults who had never smoked cigarettes, 3.2% had ever tried an e-cigarette. Ever having used an e-cigarette
was highest among never smokers aged 18–24 (9.7%) and declined with age.Image source: The website of the National Cancer Institute
(http://www.cancer.gov)The Tobacco Endgame
This is not a new concept, but it’s one that we haven’t dis-
cussed before in this column. The ActionToQuit website has
developed a newwebpage, called Tobacco Endgame (http://
actiontoquit.org/trending/endgame/). The endgame vision,
around for a long time, was the focus of a 2010 editorial by
Ruth E. Malone of the UCSF Department of Social and
Behavioral Sciences, “Imagining things otherwise: new
endgame ideas for tobacco control.”3 The concept, about
innovative strategies, new visions, and creative attacks on
many fronts against the tobacco industry (rather like Big
Tobacco strategy itself) has picked up momentum, coming
up in subsequent literature, policy statements, advocacy,
and debate. Margaret Chan, the director-general of the
WHO, spoke of the endgame in her 2013 address to the
International Conference on Public Health Priorities in New Delhi.4 Among many powerful things she said is:
“If all the harms caused by tobacco were known earlier on, tobacco products would never have been approved as safe
for human consumption, could never have been marketed and sold like any other consumer product.”
This resonates with a tempting quote that is everywhere on the Internet but hard to reference from the slightly
ﬂimsy (at least online) attributions to the Oxford Medical Companion, 1994:
“Tobacco is the only legally available consumer product which kills people when used entirely as intended.”
A request has gone in for a copy of the Companion for veriﬁcation. But as a kick-start to an endgame, that statement
can’t be beaten. The ActionToQuit webpage is worth a look with links to the literature, to Surgeon-General reports, to
January 2016 In This Issue 7the news, and to YouTube uploads. What are good endgames strategies? The US Surgeon-General’s 2014 report5
summarizes them as follows:
 Reducing nicotine yields (through gradual reduction in cigarette nicotine content, mandated at government level)
 Reducing toxicity (through regulatory standards)
 Phasing out tobacco supply
 Prohibiting sales to future generations (already planned for implementation in Tasmania6)
 Banning product sales; and
 Selling tobacco through a not-for-proﬁt agency.
Imagine!
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